Allergy drugs more harmful than helpful for chronic ear inflammation

October 17, 2006

Children who have persistent fluid in the middle ear, a condition called otitis media with effusion, are more likely to be harmed than helped by antihistamines and decongestants, a new review of studies has found.

The drugs are no better than placebo in alleviating symptoms or avoiding complications of OME and expose children to a significant risk of drug-related side effects.

"This review finds no benefit for any of the short- or long-term outcomes, including resolution of the fluid, hearing problems or the necessity of additional referral to specialists," concluded review authors led by Glenn Griffin, M.D., of Quinte West Medical Centre in Ontario, Canada. "However, treated study subjects experienced 11 percent more side effects than untreated subjects."

The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates research in all aspects of health care. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing trials on a topic.

Otitis media with effusion is one of the most common conditions affecting young children, and about nine of 10 children will have OME at least once before school age. While OME usually is not painful, the presence of fluid in the middle ear can cause problems with hearing and balance.

Antihistamines and decongestants, commonly used to treat symptoms of allergies and colds, are sometimes prescribed for OME. According to the review authors, these drugs theoretically could alleviate congestion and decrease obstruction of the Eustachian tube, allowing drainage of fluid.

The reviewers pooled the results of 15 randomized controlled trials involving 1,516 children that compared antihistamines, decongestants or the combination to a placebo for otitis media with effusion.

The findings were consistently negative. Children who received decongestants alone or in combination with antihistamines were no more likely to be cured within one month than children who received a placebo. The same results were seen when children were evaluated at one to three months or after more than three months.

Likewise, for each of the other major outcomes the reviewers examined -- hearing loss, risk of recurrent OME, development of acute otitis media and the need for surgery to drain fluid from the middle ear -- the drugs performed no better than placebo. In fact, for hearing loss, there was a trend toward worse outcomes among the children who received medication.

In parallel with the consistent lack of benefit, the reviewers also found a significant risk of harm. In the six studies that evaluated side effects, 17 percent of children who received medication suffered side effects, compared with 6 percent of children who received a placebo.

The 11 percent difference in side effects means that for every nine children treated with these drugs, one would be harmed while none would benefit.

The results of this review came as no surprise to Richard Rosenfeld, M.D., director of pediatric otolaryngology at Long Island College Hospital in Brooklyn, N.Y. The real surprise, he said, is that physicians continue to prescribe these medications for a condition that in the vast majority of cases resolves on its own.

The 2004 American Academy of Pediatrics guideline for OME, for which Rosenfeld was co-chairman, recommended against the use of antihistamines and decongestants for OME based on the preponderance of harm over benefit. A 1994 guideline also found no data supporting the use of these drugs.

"There is absolutely no question that these products don't work," said Rosenfeld. "We have a very old, very consistent body of knowledge, all of which says the same thing, and yet these products are still commonly used by practicing clinicians."

According to Rosenfeld, the continuing use of these drugs despite no evidence of benefit is a classic example of the way in which mental images can trump the best research.

"Parents will say, 'My doctor gave me these medications to dry up the fluid,' or, 'If I use this, it's going to open the Eustachian tube.' Apparently that mental image is so powerful that it completely overwhelms common sense regarding the management of this disorder."

The best-documented side effects of antihistamines and decongestants are insomnia, hyperactivity, drowsiness, behavioral changes and variability in blood pressure.

"These are pretty ubiquitous and nontrivial effects that can impair a child's functioning at home and at school," said Rosenfeld. "If you're going to subject your child to any medication that has the potential for harm, there needs to be some assurance of benefit. Don't use ineffective medications just because you have nice visual images. You're better off doing nothing."
-end-
By Kelly Griffin, Contributing Writer Health Behavior News Service

Griffin GH, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews 2006, Issue 4.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Center for Advancing Health

Related Hearing Loss Articles from Brightsurf:

Proof-of-concept for a new ultra-low-cost hearing aid for age-related hearing loss
A new ultra-affordable and accessible hearing aid made from open-source electronics could soon be available worldwide, according to a study published September 23, 2020 in the open-access journal PLOS ONE by Soham Sinha from the Georgia Institute of Technology, Georgia, US, and colleagues.

Ultra-low-cost hearing aid could address age-related hearing loss worldwide
Using a device that could be built with a dollar's worth of open-source parts and a 3D-printed case, researchers want to help the hundreds of millions of older people worldwide who can't afford existing hearing aids to address their age-related hearing loss.

Understanding the link between hearing loss and dementia
Scientists have developed a new theory as to how hearing loss may cause dementia and believe that tackling this sensory impairment early may help to prevent the disease.

Study uncovers hair cell loss as underlying cause of age-related hearing loss
In a study of human ear tissues, scientists have demonstrated that age-related hearing loss is mainly caused by damage to hair cells.

Hair cell loss causes age-related hearing loss
Age-related hearing loss has more to do with the death of hair cells than the cellular battery powering them wearing out, according to new research in JNeurosci.

How hearing loss in old age affects the brain
If your hearing deteriorates in old age, the risk of dementia and cognitive decline increases.

Examining associations between hearing loss, balance
About 3,800 adults 40 and older in South Korea participating in a national health survey were included in this analysis that examined associations between hearing loss and a test of their ability to retain balance.

Veterinarians: Dogs, too, can experience hearing loss
Just like humans, dogs are sometimes born with impaired hearing or experience hearing loss as a result of disease, inflammation, aging or exposure to noise.

Victorian child hearing-loss databank to go global
A unique databank that profiles children with hearing loss will help researchers globally understand why some children adapt and thrive, while others struggle.

Hearing loss, dementia risk in population of Taiwan
A population-based study using data from the National Health Insurance Research Database of Taiwan suggests hearing loss is associated with risk of dementia.

Read More: Hearing Loss News and Hearing Loss Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.